Martin Bittner, Arctoris

"Right now in drug discovery, we talk about failure rates of 95%, and that situation's not sustainable for two reasons. One is that a lot of the easy targets have already been worked on, which means we need to think more creatively about drug discovery. At the same time, we're moving very rapidly towards precision medicine, which means we need to discover more drugs. We must redesign the process."

Martin Bittner is the CEO and co-founder of Arctoris, where he and his team have developed the world's first fully automated drug discovery platform.

Martin talked to us about the origins of the company, how robotics and automation encourage scientific reproducibility, and where he found his mentors.

Enjoy!